---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-037034"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T19:11:56.799600+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals appoints Renee P. Tannenbaum to Board of Directors

## Summary
- Board expanded from 8 to 9 members; Dr. Tannenbaum appointed effective March 19, 2022.
- Received initial restricted stock award with $435,000 grant date fair value, vesting over 3 years.
- Dr. Tannenbaum brings over 35 years pharma experience; previously at Halozyme, AbbVie, Novartis, BMS, Merck.
- Appointment supports commercialization of Purified Cortrophin Gel, according to board chair.
- Dr. Tannenbaum determined independent under Nasdaq rules; no committee assignment yet.

## SEC filing metadata
- accession: 0001104659-22-037034
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000110465922037034/0001104659-22-037034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000110465922037034/tm2210247d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-037034
- JSON: https://secwatch.observer/filing/0001104659-22-037034.json
- Plain text: https://secwatch.observer/filing/0001104659-22-037034.txt

## Key facts
- Executive change
  Renee P. Tannenbaum was appointed as Director at ANI PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Director
  source text: On March 19, 2022, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) increased the size of the Board from eight to nine members and appointed Renee P. Tannenbaum, Pharm.D., a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000110465922037034/0001104659-22-037034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.